8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 19, 2004

BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Indiana	0-23357	35-1345024
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)
2701 Kent Avenue West Lafayette, Indiana		47906-1382
(Address of principal executive offices)		(Zip Code)
	(765) 463-4527
	(Registrant's telephone number, including area code)

The information in this Form 8-K is being furnished and shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 7.    Financial Statements and Exhibits.

         (a)        Not applicable.

         (b)        Not applicable.

         (c)        Exhibits

         99.1      Bioanalytical Systems, Inc. press release, issued August 19, 2004.

Item 9.    Regulation FD Disclosure.

On August 19, 2004, Bioanalytical Systems, Inc. (the "Company") issued a press release announcing that Gayl W. Doster has been elected to its Board of Directors.

The full text of the press release is furnished as exhibit 99.1 to this Form 8-K.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  August 19, 2004 Bioanalytical Systems, Inc.



By:  /s/ Michael R. Cox Michael R. Cox
VP-Finance, Chief Financial Officer and
Treasurer

Exhibit Index

Exhibit No.

99.1 Description

Bioanalytical Systems, Inc. press release, issued August 19, 2004.

EX-99

Bioanalytical Systems Elects Gayl W. Doster to Board of Directors

WEST LAFAYETTE, Ind., August 19, 2004 Bioanalytical Systems, Inc. (Nasdaq: BASI - NEWS) announced today that Gayl W. Doster has been elected to its Board of Directors. Mr. Doster joins as an independent director.

Mr. Doster is the former President of Sigma Micro Corporation, President and COO of Brooks Drug, and Executive VP and CFO of Hook-SupeRx, Inc. He is currently a member of the Board of Directors of Meta Group, Inc. and has served on the Board of Capital Properties.

Mr. Doster was inducted into the American Institute of Certified Public Accountants Business and Industry Hall of Fame in 2000 recognizing more than three decades of outstanding service. He has also been named an Outstanding Member in Industry of the Indiana CPA Society where he currently serves as Chair of the Joint Task Force on Regulation.

BASi Chairman Dr. Peter T. Kissinger commented, "Gayl's enthusiasm to join BASi as we evolve into something much bigger is gratifying. He brings operating and administrative muscle to our already technically excellent team. We are all looking forward to his insight and counsel."

In connection with his election as a director, BASi granted Mr. Doster an option to purchase 5,000 BASi Common Shares at the per-share market price at the close of business on August 19, 2004.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development and medical device companies. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit http://www.bioanalytical.com for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the development of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

Contact:
    Bioanalytical Systems, Inc.
    Alice Schwind, 765-497-8458
    alice@bioanalytical.com